Antiva raises $53M Series E to fund studies for HPV candidate

Antiva Biosciences has picked up another $53 million to bankroll two key studies of its topical drug for high-risk HPV infections and pre-cancerous lesions. The decade-old South San Francisco biotech will test ABI-2280 in a global Phase II clinical trial in high-grade precancerous cervical lesions — known as cervical intraepithelial…

...

Click to view original post